Rhode Island Senate Bill S2384

Rhode Island 2026 Regular Session

• Introduced: 1/30/26
• Refer: 1/30/26

Caption

Prohibits the state, participating ERISA, or any health plan from purchasing referenced drugs for a cost higher than the referenced rate.

Impact

Should S2384 be enacted, it would modify existing state laws regarding drug pricing. The implications include a prohibited practice where state-run health entities could not purchase prescribed drugs above a maximum fair price defined federal guidelines. This should theoretically lead to lowered drug prices for consumers and a reduction in financial strain on state-funded health programs. The legislation also mandates that any savings resulting from these restrictions must be passed on to consumers, further promoting affordability in the pharmaceutical market.

Summary

S2384, titled 'Prescription Drug Cost Protection', seeks to address the significant issue of high prescription drug prices in Rhode Island. The bill aims to protect residents from excessive costs, which the legislature identifies as a barrier to accessing necessary medications. By establishing limits on how much the state and various health plans can pay for referenced drugs, the bill intends to ensure that prices remain within reasonable levels, thus supporting public health and economic stability for individuals relying on these medications.

Contention

There may be contentious points surrounding S2384, particularly regarding its enforcement mechanisms and penalties for manufacturers who might attempt to circumvent the law. Concerns have been raised about the potential for drug manufacturers to withdraw products from the market in response to price ceilings, which could limit availability. Moreover, the requirement for good faith negotiations with manufacturers may raise questions about compliance and the willingness of companies to engage under potentially restrictive conditions.